Premium Nahrungsergänzungsmittel | artgerecht

Isocitrate – Function, Role & Medical Significance

Isocitrate is a key intermediate in the citric acid cycle, playing a central role in cellular energy metabolism and cancer biology.

Regular tips about health Regular tips about health

Things worth knowing about "Isocitrate"

Isocitrate is a key intermediate in the citric acid cycle, playing a central role in cellular energy metabolism and cancer biology.

What is Isocitrate?

Isocitrate is an organic molecule that serves as an intermediate in the citric acid cycle (also known as the Krebs cycle or tricarboxylic acid cycle, TCA cycle). This fundamental biochemical pathway takes place in the mitochondria of cells and is essential for generating energy from nutrients. Isocitrate is formed from citrate through an enzymatic rearrangement catalyzed by the enzyme aconitase, making it a direct downstream product in the cycle.

Biochemical Function and Mechanism of Action

Within the citric acid cycle, isocitrate is oxidatively decarboxylated by the enzyme isocitrate dehydrogenase (IDH). This reaction produces α-ketoglutarate (2-oxoglutarate), while simultaneously releasing NADH and CO&sub2;. NADH is a vital electron carrier that is subsequently used in the electron transport chain to generate ATP – the universal energy currency of the cell.

There are two main forms of isocitrate dehydrogenase:

IDH1: Found in the cytoplasm and peroxisomes; uses NADP⁺ as a cofactor.
IDH2 and IDH3: Located in the mitochondria; IDH3 is the primary enzyme active in the TCA cycle and uses NAD⁺.

Medical Significance

While isocitrate is primarily known as a biochemical intermediate, it has gained considerable importance in modern medicine due to mutations in the isocitrate dehydrogenase genes (IDH1 and IDH2). These mutations lead to the production of the oncometabolite 2-hydroxyglutarate, which disrupts normal cellular regulation and promotes the development of certain cancers.

Gliomas and glioblastomas: IDH mutations are frequently detected in certain brain tumors and serve as important diagnostic and prognostic markers.
Acute myeloid leukemia (AML): IDH1 and IDH2 mutations also occur in this blood cancer and are targets for specific therapies.
Other tumors: IDH mutations have been described in chondrosarcomas, cholangiocarcinomas, and other tumor types.

Diagnostic Relevance

Detection of IDH mutations in tumor tissue is now a key component of molecular pathological diagnostics. It is performed using immunohistochemistry or molecular genetic methods such as sequencing. The oncometabolite 2-hydroxyglutarate can also be measured in blood or tissue as an indirect marker for IDH mutations. The current WHO classification of brain tumors defines IDH mutation status as a central classification criterion.

Therapeutic Approaches

Because IDH mutations are directly involved in tumor development, specific IDH inhibitors have been developed:

Ivosidenib (IDH1 inhibitor) and Enasidenib (IDH2 inhibitor) are approved medications for the treatment of IDH-mutated acute myeloid leukemia.
Additional IDH inhibitors (e.g., olutasidenib, vorasidenib) are in clinical development or undergoing regulatory review for various tumor entities.

References

Losman J.A., Kaelin W.G. - What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Development, 2013.
World Health Organization (WHO) - Classification of Tumours of the Central Nervous System, 5th Edition, 2021.
Waitkus M.S., Diplas B.H., Yan H. - Isocitrate dehydrogenase mutations in gliomas. Neuro-Oncology, 2016.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.